REG - Creo Medical Group - First in-human milestone for MicroBlate™ Flex

Creo MedicalAnnouncement

23/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230523:nRSW2667Aa&default-theme=true

RNS Number : 2667A  Creo Medical Group PLC  23 May 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

First in-human milestone reached for MicroBlate™ Flex as part of Lung
Tissue ablation clinical study

 

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that, further to the update of
31 March 2023
(https://otp.tools.investis.com/clients/uk/creo_medical1/rns/regulatory-story.aspx?cid=2071&newsid=1678351)
, the first in-human use of the Company's MicroBlate Flex device for the
microwave (MW) ablation of soft tissue lung lesions was successfully
completed at Royal Brompton Hospital, part of Guy's and St Thomas' NHS
Foundation Trust, by Professor Pallav L Shah.

 

Creo's MicroBlate Flex device is a new soft tissue ablation device which is
designed with the aim of being able to ablate nodules and tumors in several
tissue types using the highest frequency MW energy for tumour ablation.

 

The aforementioned procedure forms part of a multi-site clinical trial, with
all patients having regular follow-up assessments post-procedure to monitor
their progress. The Study(1) is the first of a number of planned studies
regarding the Company's suite of ablation devices during 2023 and beyond.

 

Craig Gulliford, Chief Executive Officer of Creo, commented: "This is another
landmark moment for Creo Medical. Lung cancer has the second highest incidence
of the top 5 cancers and one of the lowest 5-year survival rates. Unlike most
other cancers; there are no significant, accurate screening programmes in
place for lung cancer but with screening, diagnosis and navigation technology
advancing dramatically over recent years, we are set to see that change.

"The goal of screening is to find the disease early when the tumours are
small. However, currently the treatment options for these early-stage lesions
are inappropriately invasive, typically involving chemotherapy, radiation
therapy, surgery or a combination thereof.

 

"MicroBlate Flex has been designed for a range of different applications,
including the capability of operating with these new lung cancer diagnosis and
navigation technologies, and is ideal for the targeted ablation of
pre-cancerous and potentially cancerous lesions in the lung and in other soft
tissue. Like with all our products now in clinical practice in the
gastroenterology market, we hope that our technology will enable clinicians to
significantly impact on the improvement of Cancer outcomes.

"The whole team at Creo are delighted that this clinical program has now
started. The first enrolment and MicroBlate Flex's first procedure safely
completed is an important milestone in our goal to use advanced energy to
transform lives."

Professor Shah added: "The ablate device is another tool in our armoury for
treating early lung cancers or metastatic tumours in the lung. It provides an
alternative approach when surgery is not possible and may have the potential
to create a very controlled ablation minimising any additional lung damage.
The current trial should help evaluate its safety and role in thoracic
cancers."

 

( )

(1) Bronchoscopic Microwave Ablation of Lung Tissue - Full Text View -
ClinicalTrials.gov
(https://urldefense.proofpoint.com/v2/url?u=https-3A__clinicaltrials.gov_ct2_show_NCT05786625&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=WovxkIrimZbJDsUY12yOjDzcN9uTu1TmGAhgw0TiZCY&m=OyslDpKJqy5cCdxpsKvu7ObhyVN8HFcoqPf4POVajZw&s=Nhy0JhSAmWouYJ4rmkuq8b9i6Y0LIMMiSO07LToAjiw&e=)

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFIIEAIFFIV